May 2026
📣 VC round data is live. Check it out!
Largest Public Companies in Slovakia
Benchmark revenue and EBITDA valuation multiples for public comps like
Tatra Banka, VÚB banka, Allianz-Slovenska and Zentiva.
 | Tatra Banka AS is a Slovakia-based bank that provides various banking products and services. The business activity of the bank is broken down into various segments which include Corporate Clients, Financial Institutions and Public Sector, Retail Customers, Investment Banking and Treasury, Equity Investments, and Others. The product portfolio of the company consists of account and payment services, credit card facilities, loan facilities such as consumer and home loans, and saving and investment services which comprise of term deposits, passbooks, investments in mutual funds, fixed income, and structured deposits. Business is operated through the Slovakia region and the majority of the bank's revenue is derived from net interest income with the remaining coming from fees and commissions. | $42,368 | -- | $3B | $8B | 8.6x | — | ||
| Vseobecna Uverova Banka is a Slovakia based company. The company provides retail and commercial banking services. The company operates three segments: Retail banking; Corporate Banking; Central Treasury. The company provides Loans, Cards, Insurance, saving, and insurance services. | $184 | -- | $2B | $7B | 7.5x | — | ||
| Allianz-Slovenska Poistovna AS is an insurance company. It offers insurance products ranging from life and accident insurance, insurance through private property and motor liability insurance to the insurance industry and entrepreneurs. The company serves small and medium size business and large companies. | $346 | -- | $2B | $2B | 4.0x | — | ||
| Zentiva AS is engaged in the development, production, and distribution of generic medicines. It operates in more than 25 European markets. The company therapeutic areas inlcude Cardiovascular, Central nervous system, Gastrointestinal and metabolic disorders, Anti-inflammatory and pain, Ophthalmology, Anti-infectives, Urology, Respiratory, Blood disorders, and Oncology. | -- | -- | $667M | $667M | — | — | ||
| Median | $346 | -- | $2B | $5B | 7.5x | — |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Recent Insights
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.